Robert W. Baird Issues Positive Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its price objective increased by Robert W. Baird from $95.00 to $111.00 in a report released on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other research analysts have also recently issued reports about the stock. Mizuho set a $115.00 target price on shares of LivaNova in a report on Wednesday. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a research note on Wednesday, August 5th. Barclays upgraded shares of LivaNova to a “strong-buy” rating in a report on Wednesday, October 7th. Raymond James Financial set a $120.00 price target on shares of LivaNova in a research report on Wednesday. Finally, Zacks Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $99.56.

LivaNova Trading Down 3.2%

NASDAQ LIVN opened at $91.14 on Thursday. LivaNova has a 12 month low of $48.82 and a 12 month high of $99.38. The stock has a market cap of $5.02 billion, a P/E ratio of 25.81 and a beta of 0.91. The stock’s fifty day moving average price is $79.08 and its 200-day moving average price is $73.40. The company has a current ratio of 1.46, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.17. The firm had revenue of $393.15 million during the quarter, compared to the consensus estimate of $381.13 million. LivaNova had a return on equity of 16.10% and a net margin of 13.01%. The company’s revenue was up 9.9% on a year-over-year basis. During the same period last year, the company earned $1.11 earnings per share. As a group, equities analysts forecast that LivaNova will post 3.78 EPS for the current fiscal year.

Insider Activity

In other LivaNova news, Director Brooke Story sold 2,300 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the transaction, the director owned 7,488 shares in the company, valued at approximately $609,672.96. This represents a 23.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Francesco Bianchi sold 3,500 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director directly owned 4,434 shares in the company, valued at approximately $345,896.34. The trade was a 44.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 7,450 shares of company stock valued at $591,839 over the last quarter. 0.35% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. Allworth Financial LP increased its position in LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. Root Financial Partners LLC purchased a new position in LivaNova in the third quarter worth about $32,000. Farther Finance Advisors LLC boosted its position in LivaNova by 59.7% in the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock worth $35,000 after purchasing an additional 169 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in LivaNova in the second quarter worth about $37,000. Finally, Sterling Capital Management LLC grew its stake in shares of LivaNova by 34.6% during the 3rd quarter. Sterling Capital Management LLC now owns 1,261 shares of the company’s stock valued at $96,000 after purchasing an additional 324 shares during the period. Institutional investors own 97.64% of the company’s stock.

Trending Headlines about LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q3 results topped expectations. LivaNova reported adjusted earnings of $1.23 per share, ahead of estimates of about $1.03–$1.06, and revenue of $393.15 million versus roughly $381 million expected. Revenue rose 9.9% year over year. LivaNova Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: 2026 outlook improved. The company forecast revenue growth of 9%–10% and raised its full-year EPS guidance to $4.40–$4.50, signaling confidence in continued growth. LivaNova forecasts 2026 growth and raises EPS guidance
• Positive Sentiment: Analysts raised their targets. Needham lifted its target to $112 from $93 and maintained a Buy rating; Baird raised its target to $111 from $95 and kept an Outperform rating. The revisions reflect more favorable expectations after the results and guidance update. Needham raises LivaNova price target
• Neutral Sentiment: OSA neuromodulation is a potential longer-term opportunity. Coverage highlighted LivaNova’s interest in entering this market, but the articles provided no details on timing, investment, or expected commercial impact. LivaNova eyes OSA neuromodulation entry

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.